BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 10669673)

  • 1. Decision-tree sensitivity analysis for cost-effectiveness of chest 2-fluoro-2-D-[(18)F]fluorodeoxyglucose positron emission tomography in patients with pulmonary nodules (non-small cell lung carcinoma) in Japan.
    Kosuda S; Ichihara K; Watanabe M; Kobayashi H; Kusano S
    Chest; 2000 Feb; 117(2):346-53. PubMed ID: 10669673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma.
    Gambhir SS; Hoh CK; Phelps ME; Madar I; Maddahi J
    J Nucl Med; 1996 Sep; 37(9):1428-36. PubMed ID: 8790186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decision-tree sensitivity analysis for cost-effectiveness of whole-body FDG PET in the management of patients with non-small-cell lung carcinoma in Japan.
    Kosuda S; Ichihara K; Watanabe M; Kobayashi H; Kusano S
    Ann Nucl Med; 2002 Jun; 16(4):263-71. PubMed ID: 12126096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Decision tree sensitivity analysis for cost-effectiveness of chest FDG-PET in patients with a pulmonary tumor (non-small cell carcinoma)].
    Kosuda S; Ichihara K; Watanabe M; Kobayashi H; Kusano S
    Kaku Igaku; 1998 Jul; 35(6):395-404. PubMed ID: 9753918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis.
    Scott WJ; Shepherd J; Gambhir SS
    Ann Thorac Surg; 1998 Dec; 66(6):1876-83; discussion 1883-5. PubMed ID: 9930463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical economics of whole-body FDG PET in patients suspected of having non-small cell lung carcinoma--reassessment based on the revised Japanese national insurance reimbursement system.
    Abe K; Kosuda S; Kusano S
    Ann Nucl Med; 2003 Dec; 17(8):649-55. PubMed ID: 14971606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should mediastinoscopy actually be incorporated into the FDG PET strategy for patients with non-small cell lung carcinoma?
    Hayashi K; Abe K; Yano F; Watanabe S; Iwasaki Y; Kosuda S
    Ann Nucl Med; 2005 Jul; 19(5):393-8. PubMed ID: 16164196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accuracy and cost-effectiveness of [18F]-2-fluoro-deoxy-D-glucose-positron emission tomography scan in potentially resectable non-small cell lung cancer.
    Kelly RF; Tran T; Holmstrom A; Murar J; Segurola RJ
    Chest; 2004 Apr; 125(4):1413-23. PubMed ID: 15078754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of strategies introducing integrated ¹⁸F-FDG PET/CT into the mediastinal lymph node staging of non-small-cell lung cancer.
    Han Y; Xiao H; Zhou Z; Yuan M; Zeng Y; Wu H; Fang Y
    Nucl Med Commun; 2015 Mar; 36(3):234-41. PubMed ID: 25460305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis models to assess cost effectiveness of the four strategies for the work-up of solitary pulmonary nodules.
    Tsushima Y; Endo K
    Med Sci Monit; 2004 May; 10(5):MT65-72. PubMed ID: 15114278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of positron emission tomography for non-small cell lung carcinoma in Canada.
    Sloka JS; Hollett PD; Mathews M
    Med Sci Monit; 2004 May; 10(5):MT73-80. PubMed ID: 15114279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [PET with (18)F-fluorodeoxyglucose for staging of non-small cell lung cancer].
    Weber WA; Dietlein M; Hellwig D; Kirsch CM; Schicha H; Schwaiger M
    Nuklearmedizin; 2003 Aug; 42(4):135-44. PubMed ID: 12937692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic analyses on the use of positron emission tomography for the work-up of solitary pulmonary nodules and for staging patients with non-small-cell-lung-cancer in Italy.
    Gugiatti A; Grimaldi A; Rossetti C; Lucignani G; De Marchis D; Borgonovi E; Fazio F
    Q J Nucl Med Mol Imaging; 2004 Mar; 48(1):49-61. PubMed ID: 15195004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of strategies introducing FDG-PET into the mediastinal staging of non-small-cell lung cancer from the French healthcare system perspective.
    Alzahouri K; Lejeune C; Woronoff-Lemsi MC; Arveux P; Guillemin F
    Clin Radiol; 2005 Apr; 60(4):479-92. PubMed ID: 15767106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: an economic evaluation.
    van Loon J; Grutters JP; Wanders R; Boersma L; Dingemans AM; Bootsma G; Geraedts W; Pitz C; Simons J; Brans B; Snoep G; Hochstenbag M; Lambin P; De Ruysscher D
    Eur J Cancer; 2010 Jan; 46(1):110-9. PubMed ID: 19944595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results.
    Dietlein M; Weber K; Gandjour A; Moka D; Theissen P; Lauterbach KW; Schicha H
    Eur J Nucl Med; 2000 Nov; 27(11):1598-609. PubMed ID: 11105815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decision analysis for the cost-effective management of recurrent colorectal cancer.
    Park KC; Schwimmer J; Shepherd JE; Phelps ME; Czernin JR; Schiepers C; Gambhir SS
    Ann Surg; 2001 Mar; 233(3):310-9. PubMed ID: 11224617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study.
    Verboom P; van Tinteren H; Hoekstra OS; Smit EF; van den Bergh JH; Schreurs AJ; Stallaert RA; van Velthoven PC; Comans EF; Diepenhorst FW; van Mourik JC; Postmus PE; Boers M; Grijseels EW; Teule GJ; Uyl-de Groot CA;
    Eur J Nucl Med Mol Imaging; 2003 Nov; 30(11):1444-9. PubMed ID: 14579081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PET-FDG scan enhances but does not replace preoperative surgical staging in non-small cell lung carcinoma.
    Poncelet AJ; Lonneux M; Coche E; Weynand B; Noirhomme P;
    Eur J Cardiothorac Surg; 2001 Sep; 20(3):468-74; discussion 474-5. PubMed ID: 11509265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.